{"title":"抗磷脂综合征的产科注意事项和处理","authors":"Karen J. Gibbins, R. Silver","doi":"10.2174/1874303X01508020022","DOIUrl":null,"url":null,"abstract":"Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-s 2 - glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.","PeriodicalId":38952,"journal":{"name":"Open Urology and Nephrology Journal","volume":"8 1","pages":"22-26"},"PeriodicalIF":0.0000,"publicationDate":"2015-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Obstetrical Considerations and Management of Antiphospholipid Syndrome\",\"authors\":\"Karen J. Gibbins, R. Silver\",\"doi\":\"10.2174/1874303X01508020022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-s 2 - glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.\",\"PeriodicalId\":38952,\"journal\":{\"name\":\"Open Urology and Nephrology Journal\",\"volume\":\"8 1\",\"pages\":\"22-26\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-02-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Urology and Nephrology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874303X01508020022\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Urology and Nephrology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874303X01508020022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
抗磷脂综合征是一种促血栓形成、促炎症的疾病,至少有一项临床标准和一项实验室发现。符合临床标准的有血栓形成史或产科发病史,包括复发性早孕流产、胎儿死亡或因先兆子痫或胎盘功能不全导致妊娠34周前分娩。实验室标准是狼疮抗凝血或高滴度抗心磷脂或抗s2 -糖蛋白- i IgG或IgM的证据。妊娠期间的治疗主要是基于抗凝治疗,根据血栓形成的历史使用预防性或治疗性剂量。这种治疗当然可以降低血栓形成的风险,也可以改善产科结果。
Obstetrical Considerations and Management of Antiphospholipid Syndrome
Antiphospholipid syndrome is a pro-thrombotic, pro-inflammatory condition defined by at least one clinical criterion and one laboratory finding. Clinical criteria are met by history of thrombosis or obstetric morbidity, including recurrent early pregnancy loss, fetal death, or delivery prior to 34 weeks gestation due to pre-eclampsia or placental insufficiency. Laboratory criteria are evidence of lupus anticoagulant or high titers of anticardiolipin or anti-s 2 - glycoprotein-I IgG or IgM. Treatment during pregnancy is primarily based on anticoagulant therapy, either at prophylactic or therapeutic doses depending on thrombosis history. This treatment certainly reduces thrombosis risk and may also improve obstetric outcome.